|
Publication |
|
First-Line Immune Combination Therapies for Nonclear Cell Versus Clear Cell Metastatic Renal Cell Carcinoma: Real-World Multicenter Data From Germany. Cano Garcia C, Hoeh B, Mandal S, Banek S, Klümper N, Schmucker P, Hahn O, Mattigk A, Ellinger J, Cox A, Becker P, Zeuschner P, Zengerling F, Erdmann K, Buerk BT, Kalogirou C, Flegar L. Clin Genitourin Cancer. 2024 Aug;22(4):102112. doi: 10.1016/j.clgc.2024.102112. Epub 2024 May 4.
|
|
Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions. Hoeh B, Garcia CC, Banek S, Klümper N, Cox A, Ellinger J, Schmucker P, Hahn O, Mattigk A, Zengerling F, Becker P, Erdmann K, Buerk BT, Flegar L, Huber J, Kalogirou C, Zeuschner P. Clin Transl Immunology. 2023 Oct 25;12(10):e1471. doi: 10.1002/cti2.1471. eCollection 2023.
|
|
Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. Hoeh B, Schmucker P, Klümper N, Hahn O, Zeuschner P, Banek S, Karakiewicz PI, Ellinger J, Heinzelbecker J, Hölzel M, Strauß A, Zengerling F, Mattigk A, Kalogirou C. Urol Int. 2022;106(11):1150-1157. doi: 10.1159/000521661. Epub 2022 Feb 14.
|
|
HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings. Boschert V, Teusch J, Aljasem A, Schmucker P, Klenk N, Straub A, Bittrich M, Seher A, Linz C, Müller-Richter UDA, Hartmann S. Int J Mol Sci. 2020 Nov 20;21(22):8770. doi: 10.3390/ijms21228770.
|
|
| | Last update Publications 08.06.2024 |
|